Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/53267
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects |
Author: | Guy, B. Nougarede, N. Begue, S. Sanchez, V. Souag, N. Carre, M. Chambonneau, L. Morrisson, D. Shaw, D. Qiao, M. Dumas, R. Lang, J. Forrat, R. |
Citation: | Vaccine, 2008; 26(45):5712-5721 |
Publisher: | Elsevier Sci Ltd |
Issue Date: | 2008 |
ISSN: | 0264-410X 1873-2518 |
Statement of Responsibility: | Bruno Guy, Nolwenn Nougarede, Sarah Begue, Violette Sanchez, Nadia Souag, Murielle Carre, Laurent Chambonneau, Dennis N. Morrisson, David Shaw, Ming Qiao, Rafaele Dumas, Jean Lang and Remi Forrat |
Abstract: | Three independent, phase 1 clinical trials were conducted in Australia and in USA to assess the safety and immunogenicity of sanofi pasteur dengue vaccine candidates. In this context, Dengue 1-4 and Yellow Fever 17D-204 (YF 17D)-specific CD4 and CD8 cellular responses induced by tetravalent chimeric dengue vaccines (CYD) were analyzed in flavivirus-naive or flavivirus-immune patients. Tetravalent CYD vaccine did not trigger detectable changes in serum pro-inflammatory cytokines, whatever the vaccinees immune status, while inducing significant YF 17D NS3-specific CD8 responses and dengue serotype-specific T helper responses. These responses were dominated by serotype 4 in naive individuals, but a booster vaccination (dose #2) performed 4 months following dose #1 broadened serotype-specific responses. A similar, broader response was seen after primary tetravalent immunization in subjects with pre-existing dengue 1 or 2 immunity caused by prior monovalent live-attenuated dengue vaccination. In all three trials, the profile of induced response was similar, whatever the subjects' immune status, i.e. an absence of Th2 response, and an IFN-gamma/TNF-alpha ratio dominated by IFN-gamma, for both CD4 and CD8 responses. Our results also showed an absence of cross-reactivity between YF 17D or Dengue NS3-specific CD8 responses, and allowed the identification of 3 new CD8 epitopes in the YF 17D NS3 antigen. These data are consistent with the previously demonstrated excellent safety of these dengue vaccines in flavivirus-naive and primed individuals. |
Keywords: | Dengue vaccine Human Cellular immunity |
DOI: | 10.1016/j.vaccine.2008.08.019 |
Published version: | http://dx.doi.org/10.1016/j.vaccine.2008.08.019 |
Appears in Collections: | Aurora harvest 5 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.